Prevalence of sporadic inclusion body myositis and factors contributing to delayed diagnosis

The prevalence of sporadic inclusion body myositis (sIBM) is variable in different populations and ethnic groups. A previous survey in Western Australia in 2000 found a prevalence of 9.3 per million population. We have now performed a follow-up survey to determine whether there has since been any change in prevalence. The current prevalence was found to be 14.9 per million population, with a prevalence of 51.3 per million population in people over 50 years of age. This is the highest reported prevalence of sIBM and correlates with a high frequency of HLA-DR3 and the 8.1 major histocompatibility complex ancestral haplotype in this population. Review of a combined cohort of 57 sIBM cases from three Australian centres revealed a high rate of initial misdiagnosis and a mean time to diagnosis of 5.2 years, which suggests that even the latest prevalence figure may be an underestimate, and emphasising the need to increase the level of awareness of the condition among the medical community.

[1]  K J Felice,et al.  Inclusion Body Myositis in Connecticut: Observations in 35 Patients During an 8-Year Period , 2001, Medicine.

[2]  W J Litchy,et al.  Inclusion body myositis. Observations in 40 patients. , 1989, Brain : a journal of neurology.

[3]  R. Lovelace,et al.  Inclusion body myositis mimicking motor neuron disease. , 2001, Archives of neurology.

[4]  R. Gherardi,et al.  Inclusion body myositis in French patients. A clinicopathological evaluation , 1990, Neuropathology and applied neurobiology.

[5]  D Middleton,et al.  New allele frequency database: http://www.allelefrequencies.net. , 2003, Tissue antigens.

[6]  F. Breedveld,et al.  Epidemiology of inclusion body myositis in the Netherlands: A nationwide study , 2000, Neurology.

[7]  F L Mastaglia,et al.  HLA associations with inclusion body myositis , 1994, Clinical and experimental immunology.

[8]  Derek Middleton,et al.  New allele frequency database: www.allelefrequencies.net , 2003 .

[9]  S. Dimauro,et al.  Inclusion body myositis and myopathies , 1995, Annals of neurology.

[10]  F. Mastaglia,et al.  Sporadic inclusion body myositis in Japanese is associated with the MHC ancestral haplotype 52.1 , 2006, Neuromuscular Disorders.

[11]  M. Dalakas,et al.  HLA allele distribution distinguishes sporadic inclusion body myositis from hereditary inclusion body myopathies , 1998, Journal of Neuroimmunology.

[12]  Frank L Mastaglia,et al.  Inclusion body myositis: current pathogenetic concepts and diagnostic and therapeutic approaches , 2007, The Lancet Neurology.

[13]  Y. Parman,et al.  G.P.13.01 Prevalence of sporadic inclusion body myositis (s-IBM) in Turkey: A muscle biopsy based survey , 2007, Neuromuscular Disorders.

[14]  Rolf Schröder,et al.  Analysis of HLA class I and II alleles in sporadic inclusion-body myositis , 2003, Journal of Neurology.

[15]  F L Mastaglia,et al.  Prevalence of sporadic inclusion body myositis in Western Australia , 2000, Muscle & nerve.

[16]  K. Aho,et al.  Incidence of rare systemic rheumatic and connective tissue diseases in Finland , 1996, Journal of internal medicine.

[17]  F L Mastaglia,et al.  Sporadic inclusion body myositis: Phenotypic variability and influence of HLA-DR3 in a cohort of 57 Australian cases , 2008, Journal of Neurology, Neurosurgery, and Psychiatry.

[18]  J. Verschuuren,et al.  Associations with autoimmune disorders and HLA class I and II antigens in inclusion body myositis , 2004, Neurology.

[19]  T. Weitoft.  Occurrence of polymyositis in the county of Gävleborg, Sweden. , 1997, Scandinavian journal of rheumatology.